查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1438063

2030 年促红血球生成素药物市场预测：按类型、产品、分销管道、应用、最终用户和地区进行的全球分析

Erythropoietin Drugs Market Forecasts to 2030 - Global Analysis By Type (Biosimilars and Biologics), Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Other Products), Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC预测，2023年全球促红血球生成素药物市场规模将达107亿美元，预计2030年将达到256亿美元，预测期内复合年增长率为13.2%。

促红血球生成素製剂是一类包含促红血球生成素（肾臟天然产生的荷尔蒙）重组製剂的药物。这些药物旨在刺激和增加红血球合成，可有效控制与贫血相关的症状。促红血球生成素製剂可透过增加红血球数量来治疗虚弱、呼吸困难和头晕等贫血症状，从而改善患者的日常功能。

根据世界卫生组织 (WHO) 的数据，全球 42% 的 5 岁以下儿童和 40% 的孕妇患有贫血。

贫血增加

贫血是一种以红血球数量减少或血红素数量减少为特征的疾病，导致血液携氧能力下降。 EPO 製剂透过促进红血球的产生，在贫血治疗中发挥重要作用。此外，癌症患者通常会使用 EPO 製剂来控制化疗引起的贫血并提高生活品质。这些疾病的日益普及导致贫血的整体负担增加，从而推动了对 EPO 製剂的需求。

可能的副作用

促红血球生成素药物市场面临一个潜在的限制因素：与药物使用相关的副作用的发生。主要关注点之一是与服用促红血球生成素製剂相关的心血管事件风险，例如血栓症和高血压。此外，另一个潜在的副作用是发生纯红血球再生不良性贫血（PRCA），这是一种罕见但严重的疾病，其特征是红血球产生突然停止。

提高医疗保健意识

医疗保健意识的提高是促红血球生成素製剂市场的关键驱动因素。随着患者和医疗保健专业人员对包括贫血在内的健康状况的认识不断提高，人们越来越认识到促红血球生成素製剂在治疗贫血相关併发症中的重要性。此外，越来越多的患者正在寻求及时有效的治疗，其中促红血球生成素製剂发挥重要作用，例如慢性肾臟病。这些因素正在推动市场需求。

新的替代药物

随着科学和医学研究的进展，新的治疗选择，包括非药物干预和替代药物疗法越来越受到关注，挑战促红血球生成素製剂的优越性。此外，市场上生物相似药的供应和采用不断增加可能会导致定价压力和市场占有率竞争，从而影响品牌促红血球生成素製剂的收益。

COVID-19 的影响

由于COVID-19大流行，促红血球生成素製剂市场受到了重大影响。非紧急医疗程序和治疗，包括治疗贫血的促红血球生成素产品，被推迟或推迟，影响了整体市场需求。此外，药品供应链的中断、旅行限制和劳动力短缺阻碍了促红血球生成素产品的生产和分销。

肿瘤学领域预计在预测期内规模最大

预计癌症领域将占据最大份额。癌症患者经常会出现贫血，这可能是疾病本身的结果，也可能是化疗的副作用。促红血球生成素製剂，例如阿法红血球生成素，透过刺激红血球的产生来治疗癌症患者的贫血。此外，促红血球生成素治疗可改善患者健康，并可透过维持足够的携氧红血球来实现更有效的癌症治疗。

生物製药产业预计在预测期内复合年增长率最高。

预计生技药品领域将在预测期内出现良好的成长。生技药品旨在模仿促红血球生成素刺激骨髓中红血球生成的天然能力。促红血球生成素生物製药通常用于治疗与慢性肾臟病、癌症化疗和某些其他医疗状况相关的贫血。此外，生物製药，包括基于促红血球生成素的药物，透过为贫血提供有针对性的有效治疗，为患者的治疗做出了重大贡献。

比最大的地区

由于强大的医疗基础设施、技术创新和高普及率，北美在估计期间占据了最大的市场占有率。贫血症的流行，特别是在接受透析的 CKD 患者和接受癌症治疗的患者中，正在推动北美对促红血球生成素产品的需求。此外，该地区也处于生物技术和药物研究的前沿，支持促红血球生成素配方开发的持续创新。

复合年增长率最高的地区：

亚太地区预计将在预测期内实现有益成长，因为它对全球製药业做出了重大贡献。中国和印度等国家已成为促红血球生成素製剂生产和消费的主要参与者。该地区的製药业正在经历高度的研发活动，推动创新并推出新的 EPO 配方。此外，亚太地区不断发展的医疗基础设施和不断增加的医疗费用也促进了促红血球生成素製剂市场的成长。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间存在敌对关係

第五章全球促红血球生成素製剂市场：依类型

  • 生物相似药
  • 生技药品

第六章全球促红血球生成素製剂市场：副产品

  • 红血球生成素汀
  • β-促红血球生成素生成素
  • Darbepoetin汀阿尔法
  • 其他产品

第七章全球促红血球生成素药品市场：依通路分类

  • 网路药房
  • 医院药房
  • 其他分销管道

第八章全球促红血球生成素製剂市场：依应用分类

  • 血液学
  • 癌症
  • 神经病学
  • 肾臟疾病
  • 其他用途

第九章全球促红血球生成素药物市场：依最终使用者分类

  • 专科诊所
  • 医院
  • 其他最终用户

第十章全球促红血球生成素製剂市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司简介

  • Johnson & Johnson Services, Inc.
  • AstraZeneca
  • Amgen, Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc
  • LG Chem
  • F. Hoffmann-La Roche Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Intas Pharmaceuticals Ltd.
  • Dr. Reddy's Laboratories Ltd
  • Ranbaxy Laboratories
  • Roche Diagnostics
Product Code: SMRC25051

According to Stratistics MRC, the Global Erythropoietin Drugs Market is accounted for $10.7 billion in 2023 and is expected to reach $25.6 billion by 2030 growing at a CAGR of 13.2% during the forecast period. Erythropoietin drugs are a class of medications that include recombinant forms of erythropoietin, a hormone produced naturally in the kidneys. These drugs are designed to stimulate and increase the synthesis of red blood cells, making them effective in managing conditions associated with anaemia. Erythropoietin medications treat anaemia symptoms such as weakness, dyspnea, and vertigo by raising red blood cell counts, leading to improved daily functioning for patients.

According to the World Health Organization (WHO), 42% of children under the age of five and 40% of pregnant women worldwide are anemic.

Market Dynamics:

Driver:

Rising prevalence of anaemia

Anaemia is a condition characterized by a decrease in the number of red blood cells or a decrease in the amount of haemoglobin, leading to reduced oxygen-carrying capacity in the blood. EPO drugs play a crucial role in managing anaemia by stimulating the production of red blood cells. Moreover, EPO drugs are often prescribed to cancer patients to manage chemotherapy-induced anaemia and improve their quality of life. The increasing prevalence of these conditions contributes to the overall burden of anaemia in the population, thereby driving the demand for EPO drugs.

Restraint:

Potential adverse effects

The erythropoietin drug market faces potential restraints linked to the occurrence of adverse effects associated with the therapeutic use of these drugs. One significant concern is the risk of cardiovascular events, including thrombosis and hypertension, associated with the administration of erythropoietin drugs. Furthermore, another potential adverse effect is the development of pure red cell aplasia (PRCA), a rare but serious condition characterized by a sudden halt in the production of red blood cells.

Opportunity:

Increased healthcare awareness

Increased healthcare awareness serves as a pivotal driver in the erythropoietin drugs market. As awareness about health conditions, including anemia, continues to rise among patients and healthcare professionals, there is a heightened recognition of the significance of erythropoietin drugs in managing anemia-associated complications. Moreover, patients are increasingly seeking timely and effective treatments for conditions like chronic kidney disease and other disorders where erythropoietin drugs play a vital role. These factors drive market demand.

Threat:

Emerging alternatives

As scientific and medical research progresses, new therapeutic options, including non-pharmacological interventions and alternative drug therapies, are gaining attention and posing a challenge to the dominance of erythropoietin drugs. Moreover, the increasing availability and adoption of biosimilars in the market can lead to pricing pressures and market share competition, impacting the revenue of branded erythropoietin drugs.

Covid-19 Impact

The erythropoietin drug market experienced notable impacts from the COVID-19 pandemic. Non-urgent medical procedures and treatments, including those involving erythropoietin drugs for anaemia, were deferred or delayed, affecting the overall market demand. Additionally, disruptions in the pharmaceutical supply chain, restrictions on movement, and workforce shortages posed obstacles to the production and distribution of erythropoietin drugs.

The cancer segment is expected to be the largest during the forecast period

The cancer segment is estimated to hold the largest share. Cancer patients frequently experience anaemia due to the effects of the disease itself or as a side effect of chemotherapy. Erythropoietin drugs, such as epoetin-alfa, are employed to address anaemia in cancer patients by stimulating the production of red blood cells. Moreover, erythropoietin therapies improve the patient's well-being, potentially allowing for more effective cancer treatment by maintaining adequate levels of oxygen-carrying red blood cells.

The biologics segment is expected to have the highest CAGR during the forecast period

The biologics segment is anticipated to have lucrative growth during the forecast period. Biologics are designed to mimic the natural function of erythropoietin in stimulating the production of red blood cells in the bone marrow. Erythropoietin biologics are commonly used to address anaemia associated with chronic kidney disease, cancer chemotherapy, and certain other medical conditions. Additionally, biologics, including erythropoietin-based agents, contribute significantly to patient care by offering targeted and effective treatments for anaemia.

Region with largest share:

North America commanded the largest market share during the extrapolated period owing to robust healthcare infrastructure, technological innovation, and a high prevalence of conditions. The prevalence of anaemia, particularly in CKD patients undergoing dialysis and individuals undergoing cancer treatments, has fuelled the demand for erythropoietin drugs in North America. Moreover, the region is also at the forefront of biotechnological and pharmaceutical research, driving continuous innovation in erythropoietin drug development.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period, owing to its significant contribution to the global pharmaceutical industry. Countries like China and India have emerged as key players in the production and consumption of erythropoietin drugs. The region's pharmaceutical sector benefits from robust research and development activities, fostering innovation and the introduction of new EPO formulations. Additionally, the Asia-Pacific's evolving healthcare infrastructure and increasing healthcare expenditure contribute to the growth of the erythropoietin drug market.

Key players in the market

Some of the key players in the Erythropoietin Drugs Market include Johnson & Johnson Services, Inc., AstraZeneca, Amgen, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc, LG Chem, F. Hoffmann-La Roche Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd, Ranbaxy Laboratories and Roche Diagnostics.

Key Developments:

In November 2023, AstraZeneca announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases.

In September 2023, Sun Pharmaceutical Industries Limited announced that it had entered into a licence agreement with American biopharmaceutical company Pharmazz Inc to commercialise an innovative drug, Tyvalzi (Sovateltide) in India.

In January 2022, Amgen and Generate Biomedicines announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities.

In October 2020, Novartis and Molecular Partners AG announced collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners' anti-COVID-19 DARPin® program, consisting of two therapeutic candidates, MP0420 and MP0423.

Types Covered:

  • Biosimilars
  • Biologics

Products Covered:

  • Epoetin-alfa
  • Epoetin-beta
  • Darbepoetin-alfa
  • Other Products

Distribution Channels Covered:

  • Online Pharmacy
  • Hospital Pharmacy
  • Other Distribution Channels

Applications Covered:

  • Hematology
  • Cancer
  • Neurology
  • Renal Diseases
  • Other Applications

End Users Covered:

  • Speciality Clinics
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Erythropoietin Drugs Market, By Type

  • 5.1 Introduction
  • 5.2 Biosimilars
  • 5.3 Biologics

6 Global Erythropoietin Drugs Market, By Product

  • 6.1 Introduction
  • 6.2 Epoetin-alfa
  • 6.3 Epoetin-beta
  • 6.4 Darbepoetin-alfa
  • 6.5 Other Products

7 Global Erythropoietin Drugs Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Online Pharmacy
  • 7.3 Hospital Pharmacy
  • 7.4 Other Distribution Channels

8 Global Erythropoietin Drugs Market, By Application

  • 8.1 Introduction
  • 8.2 Hematology
  • 8.3 Cancer
  • 8.4 Neurology
  • 8.5 Renal Diseases
  • 8.6 Other Applications

9 Global Erythropoietin Drugs Market, By End User

  • 9.1 Introduction
  • 9.2 Speciality Clinics
  • 9.3 Hospitals
  • 9.4 Other End Users

10 Global Erythropoietin Drugs Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Johnson & Johnson Services, Inc.
  • 12.2 AstraZeneca
  • 12.3 Amgen, Inc.
  • 12.4 Novartis AG
  • 12.5 Teva Pharmaceutical Industries Ltd.
  • 12.6 Pfizer Inc
  • 12.7 LG Chem
  • 12.8 F. Hoffmann-La Roche Ltd.
  • 12.9 Sun Pharmaceutical Industries Ltd.
  • 12.10 Intas Pharmaceuticals Ltd.
  • 12.11 Dr. Reddy's Laboratories Ltd
  • 12.12 Ranbaxy Laboratories
  • 12.13 Roche Diagnostics

List of Tables

  • Table 1 Global Erythropoietin Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Erythropoietin Drugs Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Erythropoietin Drugs Market Outlook, By Biosimilars (2021-2030) ($MN)
  • Table 4 Global Erythropoietin Drugs Market Outlook, By Biologics (2021-2030) ($MN)
  • Table 5 Global Erythropoietin Drugs Market Outlook, By Product (2021-2030) ($MN)
  • Table 6 Global Erythropoietin Drugs Market Outlook, By Epoetin-alfa (2021-2030) ($MN)
  • Table 7 Global Erythropoietin Drugs Market Outlook, By Epoetin-beta (2021-2030) ($MN)
  • Table 8 Global Erythropoietin Drugs Market Outlook, By Darbepoetin-alfa (2021-2030) ($MN)
  • Table 9 Global Erythropoietin Drugs Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 10 Global Erythropoietin Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 11 Global Erythropoietin Drugs Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 12 Global Erythropoietin Drugs Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 13 Global Erythropoietin Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 14 Global Erythropoietin Drugs Market Outlook, By Application (2021-2030) ($MN)
  • Table 15 Global Erythropoietin Drugs Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 16 Global Erythropoietin Drugs Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 17 Global Erythropoietin Drugs Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 18 Global Erythropoietin Drugs Market Outlook, By Renal Diseases (2021-2030) ($MN)
  • Table 19 Global Erythropoietin Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 20 Global Erythropoietin Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 21 Global Erythropoietin Drugs Market Outlook, By Speciality Clinics (2021-2030) ($MN)
  • Table 22 Global Erythropoietin Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 23 Global Erythropoietin Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 24 North America Erythropoietin Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 25 North America Erythropoietin Drugs Market Outlook, By Type (2021-2030) ($MN)
  • Table 26 North America Erythropoietin Drugs Market Outlook, By Biosimilars (2021-2030) ($MN)
  • Table 27 North America Erythropoietin Drugs Market Outlook, By Biologics (2021-2030) ($MN)
  • Table 28 North America Erythropoietin Drugs Market Outlook, By Product (2021-2030) ($MN)
  • Table 29 North America Erythropoietin Drugs Market Outlook, By Epoetin-alfa (2021-2030) ($MN)
  • Table 30 North America Erythropoietin Drugs Market Outlook, By Epoetin-beta (2021-2030) ($MN)
  • Table 31 North America Erythropoietin Drugs Market Outlook, By Darbepoetin-alfa (2021-2030) ($MN)
  • Table 32 North America Erythropoietin Drugs Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 33 North America Erythropoietin Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 34 North America Erythropoietin Drugs Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 35 North America Erythropoietin Drugs Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 36 North America Erythropoietin Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 37 North America Erythropoietin Drugs Market Outlook, By Application (2021-2030) ($MN)
  • Table 38 North America Erythropoietin Drugs Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 39 North America Erythropoietin Drugs Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 40 North America Erythropoietin Drugs Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 41 North America Erythropoietin Drugs Market Outlook, By Renal Diseases (2021-2030) ($MN)
  • Table 42 North America Erythropoietin Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 43 North America Erythropoietin Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 44 North America Erythropoietin Drugs Market Outlook, By Speciality Clinics (2021-2030) ($MN)
  • Table 45 North America Erythropoietin Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 46 North America Erythropoietin Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 47 Europe Erythropoietin Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 48 Europe Erythropoietin Drugs Market Outlook, By Type (2021-2030) ($MN)
  • Table 49 Europe Erythropoietin Drugs Market Outlook, By Biosimilars (2021-2030) ($MN)
  • Table 50 Europe Erythropoietin Drugs Market Outlook, By Biologics (2021-2030) ($MN)
  • Table 51 Europe Erythropoietin Drugs Market Outlook, By Product (2021-2030) ($MN)
  • Table 52 Europe Erythropoietin Drugs Market Outlook, By Epoetin-alfa (2021-2030) ($MN)
  • Table 53 Europe Erythropoietin Drugs Market Outlook, By Epoetin-beta (2021-2030) ($MN)
  • Table 54 Europe Erythropoietin Drugs Market Outlook, By Darbepoetin-alfa (2021-2030) ($MN)
  • Table 55 Europe Erythropoietin Drugs Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 56 Europe Erythropoietin Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 57 Europe Erythropoietin Drugs Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 58 Europe Erythropoietin Drugs Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 59 Europe Erythropoietin Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 60 Europe Erythropoietin Drugs Market Outlook, By Application (2021-2030) ($MN)
  • Table 61 Europe Erythropoietin Drugs Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 62 Europe Erythropoietin Drugs Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 63 Europe Erythropoietin Drugs Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 64 Europe Erythropoietin Drugs Market Outlook, By Renal Diseases (2021-2030) ($MN)
  • Table 65 Europe Erythropoietin Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 66 Europe Erythropoietin Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 67 Europe Erythropoietin Drugs Market Outlook, By Speciality Clinics (2021-2030) ($MN)
  • Table 68 Europe Erythropoietin Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 69 Europe Erythropoietin Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 70 Asia Pacific Erythropoietin Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 71 Asia Pacific Erythropoietin Drugs Market Outlook, By Type (2021-2030) ($MN)
  • Table 72 Asia Pacific Erythropoietin Drugs Market Outlook, By Biosimilars (2021-2030) ($MN)
  • Table 73 Asia Pacific Erythropoietin Drugs Market Outlook, By Biologics (2021-2030) ($MN)
  • Table 74 Asia Pacific Erythropoietin Drugs Market Outlook, By Product (2021-2030) ($MN)
  • Table 75 Asia Pacific Erythropoietin Drugs Market Outlook, By Epoetin-alfa (2021-2030) ($MN)
  • Table 76 Asia Pacific Erythropoietin Drugs Market Outlook, By Epoetin-beta (2021-2030) ($MN)
  • Table 77 Asia Pacific Erythropoietin Drugs Market Outlook, By Darbepoetin-alfa (2021-2030) ($MN)
  • Table 78 Asia Pacific Erythropoietin Drugs Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 79 Asia Pacific Erythropoietin Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 80 Asia Pacific Erythropoietin Drugs Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 81 Asia Pacific Erythropoietin Drugs Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 82 Asia Pacific Erythropoietin Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 83 Asia Pacific Erythropoietin Drugs Market Outlook, By Application (2021-2030) ($MN)
  • Table 84 Asia Pacific Erythropoietin Drugs Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 85 Asia Pacific Erythropoietin Drugs Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 86 Asia Pacific Erythropoietin Drugs Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 87 Asia Pacific Erythropoietin Drugs Market Outlook, By Renal Diseases (2021-2030) ($MN)
  • Table 88 Asia Pacific Erythropoietin Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 89 Asia Pacific Erythropoietin Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 90 Asia Pacific Erythropoietin Drugs Market Outlook, By Speciality Clinics (2021-2030) ($MN)
  • Table 91 Asia Pacific Erythropoietin Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 92 Asia Pacific Erythropoietin Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 93 South America Erythropoietin Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 94 South America Erythropoietin Drugs Market Outlook, By Type (2021-2030) ($MN)
  • Table 95 South America Erythropoietin Drugs Market Outlook, By Biosimilars (2021-2030) ($MN)
  • Table 96 South America Erythropoietin Drugs Market Outlook, By Biologics (2021-2030) ($MN)
  • Table 97 South America Erythropoietin Drugs Market Outlook, By Product (2021-2030) ($MN)
  • Table 98 South America Erythropoietin Drugs Market Outlook, By Epoetin-alfa (2021-2030) ($MN)
  • Table 99 South America Erythropoietin Drugs Market Outlook, By Epoetin-beta (2021-2030) ($MN)
  • Table 100 South America Erythropoietin Drugs Market Outlook, By Darbepoetin-alfa (2021-2030) ($MN)
  • Table 101 South America Erythropoietin Drugs Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 102 South America Erythropoietin Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 103 South America Erythropoietin Drugs Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 104 South America Erythropoietin Drugs Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 105 South America Erythropoietin Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 106 South America Erythropoietin Drugs Market Outlook, By Application (2021-2030) ($MN)
  • Table 107 South America Erythropoietin Drugs Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 108 South America Erythropoietin Drugs Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 109 South America Erythropoietin Drugs Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 110 South America Erythropoietin Drugs Market Outlook, By Renal Diseases (2021-2030) ($MN)
  • Table 111 South America Erythropoietin Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 112 South America Erythropoietin Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 113 South America Erythropoietin Drugs Market Outlook, By Speciality Clinics (2021-2030) ($MN)
  • Table 114 South America Erythropoietin Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 115 South America Erythropoietin Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 116 Middle East & Africa Erythropoietin Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 117 Middle East & Africa Erythropoietin Drugs Market Outlook, By Type (2021-2030) ($MN)
  • Table 118 Middle East & Africa Erythropoietin Drugs Market Outlook, By Biosimilars (2021-2030) ($MN)
  • Table 119 Middle East & Africa Erythropoietin Drugs Market Outlook, By Biologics (2021-2030) ($MN)
  • Table 120 Middle East & Africa Erythropoietin Drugs Market Outlook, By Product (2021-2030) ($MN)
  • Table 121 Middle East & Africa Erythropoietin Drugs Market Outlook, By Epoetin-alfa (2021-2030) ($MN)
  • Table 122 Middle East & Africa Erythropoietin Drugs Market Outlook, By Epoetin-beta (2021-2030) ($MN)
  • Table 123 Middle East & Africa Erythropoietin Drugs Market Outlook, By Darbepoetin-alfa (2021-2030) ($MN)
  • Table 124 Middle East & Africa Erythropoietin Drugs Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 125 Middle East & Africa Erythropoietin Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 126 Middle East & Africa Erythropoietin Drugs Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 127 Middle East & Africa Erythropoietin Drugs Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 128 Middle East & Africa Erythropoietin Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 129 Middle East & Africa Erythropoietin Drugs Market Outlook, By Application (2021-2030) ($MN)
  • Table 130 Middle East & Africa Erythropoietin Drugs Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 131 Middle East & Africa Erythropoietin Drugs Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 132 Middle East & Africa Erythropoietin Drugs Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 133 Middle East & Africa Erythropoietin Drugs Market Outlook, By Renal Diseases (2021-2030) ($MN)
  • Table 134 Middle East & Africa Erythropoietin Drugs Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 135 Middle East & Africa Erythropoietin Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 136 Middle East & Africa Erythropoietin Drugs Market Outlook, By Speciality Clinics (2021-2030) ($MN)
  • Table 137 Middle East & Africa Erythropoietin Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 138 Middle East & Africa Erythropoietin Drugs Market Outlook, By Other End Users (2021-2030) ($MN)